Tamoxifen in cancer therapy: minireview

Affiliations

01 January 2000

-

doi: 10870680/


Abstract

Tamoxifen belongs among relatively new drugs. As it has already been shown, it undoubtedly brings a benefit to oncology patients. However, there are still questions regarding its broader use in therapy or cancer prevention. This review puts together some data available at present time with the aim of elucidating the most important aspects of its use in medical oncology.


Similar articles

Chemoprevention of breast cancer: recommendations and rationale.

[No authors listed]Am Fam Physician. 2003 Mar 15;67(6):1309-14.PMID: 12674459 Review. No abstract available.

Should you be taking tamoxifen?

[No authors listed]Johns Hopkins Med Lett Health After 50. 2001 Jun;13(4):4-5.PMID: 11439691 No abstract available.

[Primary multiple neoplasm of the endometrium and adjuvant hormone therapy in patients with breast cancer].

Bakhidze EV, Maksimov SIa, Barash NIu, Berstein LM, Semiglazov VF, Sheĭko EV, Novik VI.Vopr Onkol. 1998;44(2):170-4.PMID: 9615821 Clinical Trial. Russian.

[Is there a basis for prevention of breast cancer with drugs?].

Klemetsdal B.Tidsskr Nor Laegeforen. 1997 Apr 20;117(10):1493-5.PMID: 9198929 Norwegian.

[Tamoxifen and breast cancer: is everything known already?].

Marchetti P, Porzio G, Trapasso T, Baldi PL, Ficorella C.Tumori. 1998 Nov-Dec;84(6):A1-5.PMID: 10080686 Review. Italian. No abstract available.


Cited by

p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Alkarain A, Jordan R, Slingerland J.J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):67-80. doi: 10.1023/B:JOMG.0000023589.00994.5e.PMID: 15082919 Review.


KMEL References